CAR T-cell Therapy for HPV-Induced Metastatic Cervical Cancer

Cancer News

Research paper from the Journal of Clinical Oncology, selected by Editor in Chief George Lundberg, MD, who notes:

CAR T-cell therapy has been approved by the U.S. Food and Drug Administration (FDA) for certain hematologic malignancies. This early study demonstrates its effectiveness in human papillomavirus (HPV)-induced metastatic cervical cancer as well.

Go to full article published by the Journal of Clinical Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Back to Cancer Insights